In the case of RA, there are still no anti-IL17 approved drugs; however, there are novel approaches that are being used in the clinic, targeting cytokines such as TNF, IL-1, IL-1R, IL6, and IL6R, which have been proven to be useful [101]. This evidence concerns the gene IL17A and rheumatoid arthritis.